Matibabu ya Tiba
Study finds lecanemab clears amyloid but shows no short-term recovery in brain waste-clearance system
Imeripotiwa na AI Picha iliyoundwa na AI Imethibitishwa ukweli
Researchers at Osaka Metropolitan University report that while the Alzheimer’s drug lecanemab reduces amyloid plaques, MRI measures found no improvement in the brain’s glymphatic waste-clearance three months after treatment began, underscoring the disease’s complexity and the need for multi-target approaches.
Servier Egypt has launched Tibsovo (ivosidenib), the first targeted therapy available in the country for patients with IDH1-mutated Acute Myeloid Leukemia (AML) and intrahepatic cholangiocarcinoma. The treatment offers a median overall survival of 29.3 months for eligible AML patients and 10.3 months for those with intrahepatic cholangiocarcinoma, according to clinical data. It is approved as a first-line treatment for AML and a second-line option for intrahepatic cholangiocarcinoma.
Imeripotiwa na AI
Bi Judy Wanyoike aligundulika kuwa na saratani ya lango la uzazi hatua ya 2B mwaka 2012 baada ya uchunguzi wa Pap Smear. Licha ya upasuaji, tibakemia na tibaredio, kansa ilirudi mwaka 2019 na tena 2022. Wataalamu wanasisitiza umuhimu wa utambuzi wa mapema ili kuzuia kurudi kwa ugonjwa.